NGAM Advisors L.P. increased its position in Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) by 24.5% during the second quarter, according to its most recent filing with the SEC. The institutional investor owned 16,953 shares of the biopharmaceutical company’s stock after buying an additional 3,335 shares during the period. NGAM Advisors L.P.’s holdings in Alexion Pharmaceuticals were worth $2,063,000 at the end of the most recent quarter.

Several other large investors also recently made changes to their positions in the company. Guardian Life Insurance Co. of America raised its position in Alexion Pharmaceuticals by 0.7% in the first quarter. Guardian Life Insurance Co. of America now owns 865 shares of the biopharmaceutical company’s stock worth $105,000 after buying an additional 6 shares during the last quarter. Meeder Asset Management Inc. acquired a new position in Alexion Pharmaceuticals during the first quarter worth $111,000. Independent Portfolio Consultants Inc. raised its position in Alexion Pharmaceuticals by 46.9% in the first quarter. Independent Portfolio Consultants Inc. now owns 1,065 shares of the biopharmaceutical company’s stock worth $129,000 after buying an additional 340 shares during the last quarter. Huntington National Bank raised its position in Alexion Pharmaceuticals by 1,084.6% in the second quarter. Huntington National Bank now owns 1,078 shares of the biopharmaceutical company’s stock worth $131,000 after buying an additional 987 shares during the last quarter. Finally, FUKOKU MUTUAL LIFE INSURANCE Co raised its position in Alexion Pharmaceuticals by 10.0% in the first quarter. FUKOKU MUTUAL LIFE INSURANCE Co now owns 1,100 shares of the biopharmaceutical company’s stock worth $133,000 after buying an additional 100 shares during the last quarter. Institutional investors own 95.14% of the company’s stock.

Shares of Alexion Pharmaceuticals, Inc. (NASDAQ ALXN) opened at 132.93 on Friday. The stock’s 50 day moving average price is $129.36 and its 200 day moving average price is $122.92. Alexion Pharmaceuticals, Inc. has a 12-month low of $96.18 and a 12-month high of $145.42. The firm has a market capitalization of $29.67 billion, a price-to-earnings ratio of 57.65 and a beta of 1.41.

Alexion Pharmaceuticals (NASDAQ:ALXN) last announced its quarterly earnings results on Thursday, July 27th. The biopharmaceutical company reported $1.56 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $1.08 by $0.48. The company had revenue of $912 million during the quarter, compared to analysts’ expectations of $846.15 million. Alexion Pharmaceuticals had a return on equity of 12.47% and a net margin of 15.31%. The firm’s quarterly revenue was up 21.1% compared to the same quarter last year. During the same period in the previous year, the business earned $1.13 earnings per share. Equities research analysts expect that Alexion Pharmaceuticals, Inc. will post $5.60 earnings per share for the current year.

COPYRIGHT VIOLATION WARNING: This report was first reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this report on another domain, it was copied illegally and reposted in violation of United States & international trademark and copyright laws. The legal version of this report can be accessed at https://www.thecerbatgem.com/2017/08/13/ngam-advisors-l-p-has-2-06-million-stake-in-alexion-pharmaceuticals-inc-nasdaqalxn.html.

A number of research firms recently weighed in on ALXN. Stifel Nicolaus reissued a “buy” rating and set a $157.00 target price on shares of Alexion Pharmaceuticals in a report on Wednesday, May 24th. UBS AG reissued a “buy” rating and set a $140.00 target price (down from $143.00) on shares of Alexion Pharmaceuticals in a report on Wednesday, May 31st. Jefferies Group LLC set a $120.00 target price on Alexion Pharmaceuticals and gave the stock a “hold” rating in a report on Thursday, June 8th. Barclays PLC reissued an “overweight” rating and set a $155.00 target price on shares of Alexion Pharmaceuticals in a report on Tuesday, May 9th. Finally, J P Morgan Chase & Co reissued a “hold” rating on shares of Alexion Pharmaceuticals in a report on Wednesday, June 14th. Five analysts have rated the stock with a hold rating, nineteen have issued a buy rating and three have issued a strong buy rating to the stock. The company currently has an average rating of “Buy” and a consensus target price of $156.89.

In related news, Director Ann M. Veneman sold 700 shares of the business’s stock in a transaction dated Monday, July 31st. The stock was sold at an average price of $137.74, for a total transaction of $96,418.00. Following the completion of the transaction, the director now directly owns 6,315 shares in the company, valued at $869,828.10. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, Director Bros. Advisors Lp Baker bought 1,348,955 shares of Alexion Pharmaceuticals stock in a transaction that occurred on Wednesday, June 14th. The shares were acquired at an average price of $116.32 per share, with a total value of $156,910,445.60. The disclosure for this purchase can be found here. Over the last quarter, insiders bought 2,019,734 shares of company stock valued at $235,606,846. 4.35% of the stock is owned by company insiders.

Alexion Pharmaceuticals Company Profile

Alexion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutic products. The Company’s products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa). The Company’s clinical development programs include Soliris (eculizumab), cPMP (ALXN1101), SBC-103, ALXN1210 (IV) and ALXN1210 (Subcutaneous).

Want to see what other hedge funds are holding ALXN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN).

Institutional Ownership by Quarter for Alexion Pharmaceuticals (NASDAQ:ALXN)

Receive News & Stock Ratings for Alexion Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.